Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling

Cancer Letters

Volumn 341, Issue 2, 2013, Pages 166-177

  Macha, Muzafar A ^a   Rachagani, Satyanarayana ^a   Gupta, Suprit ^a   Pai, Priya ^a   Ponnusamy, Moorthy P ^a   Batra, Surinder K ^a,b   Jain, Maneesh ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cell proliferation; EB1; Guggulesterone; Motility; MUC4 mucin; Pancreatic cancer

Indexed keywords

CASPASE 3; CYCLIN D1; FOCAL ADHESION KINASE; GELATINASE B; GUGGULSTERONE; JANUS KINASE; LIPOCORTIN 5; MUCIN 4; PROTEIN 14 3 3; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; STAT PROTEIN; X LINKED INHIBITOR OF APOPTOSIS; CELL CYCLE PROTEIN; FOCAL ADHESION KINASE 1; ISOENZYME; MUC4 PROTEIN, HUMAN; PREGNA-4,17-DIENE-3,16-DIONE; PREGNANE DERIVATIVE; PTK2 PROTEIN, HUMAN; STAT1 PROTEIN; STAT1 PROTEIN, HUMAN; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ACTIN FILAMENT; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL DISRUPTION; CELL INVASION; CELL MOTILITY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS INHIBITION; MITOCHONDRION; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; CELL MOTION; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CYTOSKELETON; DOSE RESPONSE; DRUG EFFECTS; GENETICS; IMMUNOBLOTTING; METABOLISM; METASTASIS; PANCREAS TUMOR; PATHOLOGY; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TUMOR CELL LINE;

APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYTOSKELETON; DOSE-RESPONSE RELATIONSHIP, DRUG; FOCAL ADHESION KINASE 1; HUMANS; IMMUNOBLOTTING; ISOENZYMES; JANUS KINASES; MICROSCOPY, CONFOCAL; MUCIN-4; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PREGNENEDIONES; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STAT TRANSCRIPTION FACTORS; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS;

EID: 84887202124     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.07.037     Document Type: Article

References (58)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Mimeault M., Johansson S.L., Senapati S., Momi N., Chakraborty S., Batra S.K. MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. Cancer Lett. 2010, 295:69-84.
3. Hu G., Li F., Ouyang K., Xie F., Tang X., Wang K., Han S., Jiang Z., Zhu M., Wen D., Qin X., Zhang L. Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype. Int. J. Oncol. 2012, 40:798-806.
4. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
5. Shishodia S., Harikumar K.B., Dass S., Ramawat K.G., Aggarwal B.B. The guggul for chronic diseases: ancient medicine, modern targets. Anticancer Res. 2008, 28:3647-3664.
6. Ahn K.S., Sethi G., Sung B., Goel A., Ralhan R., Aggarwal B.B. Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res. 2008, 68:4406-4415.
7. An M.J., Cheon J.H., Kim S.W., Kim E.S., Kim T.I., Kim W.H. Guggulsterone induces apoptosis in colon cancer cells and inhibits tumor growth in murine colorectal cancer xenografts. Cancer Lett. 2009, 279:93-100.
8. Kim E.S., Hong S.Y., Lee H.K., Kim S.W., An M.J., Kim T.I., Lee K.R., Kim W.H., Cheon J.H. Guggulsterone inhibits angiogenesis by blocking STAT3 and VEGF expression in colon cancer cells. Oncol. Rep. 2008, 20:1321-1327.
9. Leeman-Neill R.J., Wheeler S.E., Singh S.V., Thomas S.M., Seethala R.R., Neill D.B., Panahandeh M.C., Hahm E.R., Joyce S.C., Sen M., Cai Q., Freilino M.L., Li C., Johnson D.E., Grandis J.R. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis 2009, 30:1848-1856.
10. Shishodia S., Aggarwal B.B. Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J. Biol. Chem. 2004, 279:47148-47158.
11. Shishodia S., Sethi G., Ahn K.S., Aggarwal B.B. Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products. Biochem. Pharmacol. 2007, 74:118-130.
12. Singh S.V., Zeng Y., Xiao D., Vogel V.G., Nelson J.B., Dhir R., Tripathi Y.B. Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, in PC-3 human prostate cancer cells is mediated by Bax and Bak. Mol. Cancer Ther. 2005, 4:1747-1754.
13. Singh S.V., Choi S., Zeng Y., Hahm E.R., Xiao D. Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase. Cancer Res. 2007, 67:7439-7449.
14. Xiao D., Singh S.V. Z-Guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, inhibits angiogenesis in vitro and in vivo. Mol. Cancer Ther. 2008, 7:171-180.
15. Lee J.Y., Lee K.T., Lee J.K., Lee K.H., Jang K.T., Heo J.S., Choi S.H., Kim Y., Rhee J.C. Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion. Br. J. Cancer. 2011, 104:1027-1037.
16. Xu H.B., Xu L.Z., Li L., Fu J., Mao X.P. Reversion of P-glycoprotein-mediated multidrug resistance by guggulsterone in multidrug-resistant human cancer cell lines. Eur. J. Pharmacol. 2012, 694:39-44.
17. Ahn D.W., Seo J.K., Lee S.H., Hwang J.H., Lee J.K., Ryu J.K., Kim Y.T., Yoon Y.B. Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer. Pancreas 2012, 41:1048-1057.
18. Yang M.H., Lee K.T., Yang S., Lee J.K., Lee K.H., Moon I.H., Rhee J.C. Guggulsterone enhances antitumor activity of gemcitabine in gallbladder cancer cells through suppression of NF-kappaB. J. Cancer Res. Clin. Oncol. 2012, 138:1743-1751.
19. Choudhuri R., Degraff W., Gamson J., Mitchell J.B., Cook J.A. Guggulsterone-mediated enhancement of radiosensitivity in human tumor cell lines. Front Oncol. 2011, 1(19):19.
20. Lv N., Song M.Y., Kim E.K., Park J.W., Kwon K.B., Park B.H. Guggulsterone, a plant sterol, inhibits NF-kappaB activation and protects pancreatic beta cells from cytokine toxicity. Mol. Cell Endocrinol. 2008, 289:49-59.
21. Macha M.A., Matta A., Chauhan S.S., Siu K.W., Ralhan R. Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-kappaB and STAT3 pathways in head and neck cancer cells. Carcinogenesis 2011, 32:368-380.
22. Kapoor S. Guggulsterone: a potent farnesoid X receptor antagonist and its rapidly evolving role as a systemic anticarcinogenic agent. Hepatology 2008, 48:2090-2091.
23. Sarfaraz S., Siddiqui I.A., Syed D.N., Afaq F., Mukhtar H. Guggulsterone modulates MAPK and NF-kappaB pathways and inhibits skin tumorigenesis in SENCAR mice. Carcinogenesis 2008, 29:2011-2018.
24. Burris T.P., Montrose C., Houck K.A., Osborne H.E., Bocchinfuso W.P., Yaden B.C., Cheng C.C., Zink R.W., Barr R.J., Hepler C.D., Krishnan V., Bullock H.A., Burris L.L., Galvin R.J., Bramlett K., Stayrook K.R. The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol. Pharmacol. 2005, 67:948-954.
25. Brobst D.E., Ding X., Creech K.L., Goodwin B., Kelley B., Staudinger J.L. Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. J. Pharmacol. Exp. Ther. 2004, 310:528-535.
26. Moniaux N., Varshney G.C., Chauhan S.C., Copin M.C., Jain M., Wittel U.A., Andrianifahanana M., Aubert J.P., Batra S.K. Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. J. Histochem. Cytochem. 2004, 52:253-261.
27. Chaturvedi P., Singh A.P., Moniaux N., Senapati S., Chakraborty S., Meza J.L., Batra S.K. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol. Cancer Res. 2007, 5:309-320.
28. Torres M.P., Ponnusamy M.P., Chakraborty S., Smith L.M., Das S., Arafat H.A., Batra S.K. Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol. Cancer Ther. 2010, 9:1419-1431.
29. Rachagani S., Macha M.A., Ponnusamy M.P., Haridas D., Kaur S., Jain M., Batra S.K. MUC4 potentiates invasion and metastasis of pancreatic cancer cells through stabilization of fibroblast growth factor receptor 1. Carcinogenesis 2012, 33:1953-1964.
30. Macha M.A., Matta A., Chauhan S., Siu K.M., Ralhan R. 14-3-3 zeta is a molecular target in guggulsterone induced apoptosis in head and neck cancer cells. BMC Cancer 2010, 10(655):655-710.
31. Andrianifahanana M., Singh A.P., Nemos C., Ponnusamy M.P., Moniaux N., Mehta P.P., Varshney G.C., Batra S.K. IFN-gamma-induced expression of MUC4 in pancreatic cancer cells is mediated by STAT-1 upregulation: a novel mechanism for IFN-gamma response. Oncogene 2007, 26:7251-7261.
32. Perrais M., Pigny P., Ducourouble M.P., Petitprez D., Porchet N., Aubert J.P., Van S. I, Characterization of human mucin gene MUC4 promoter: importance of growth factors and proinflammatory cytokines for its regulation in pancreatic cancer cells. J. Biol. Chem. 2001, 276:30923-30933.
33. Bafna S., Singh A.P., Moniaux N., Eudy J.D., Meza J.L., Batra S.K. MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. Cancer Res. 2008, 68:9231-9238.
34. Silva J., Dasgupta S., Wang G., Krishnamurthy K., Ritter E., Bieberich E. Lipids isolated from bone induce the migration of human breast cancer cells. J. Lipid Res. 2006, 47:724-733.
35. Zhao X., Guan J.L. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv. Drug Deliv. Rev. 2011, 63:610-615.
36. Nagy P., Friedlander E., Tanner M., Kapanen A.I., Carraway K.L., Isola J., Jovin T.M. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005, 65:473-482.
37. Bafna S., Kaur S., Momi N., Batra S.K. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin. Br. J. Cancer. 2009, 101:1155-1161.
38. Kossow C., Jose D., Jaster R., Wolkenhauer O., Rateitschak K. Mathematical modelling unravels regulatory mechanisms of interferon-gamma-induced STAT1 serine-phosphorylation and MUC4 expression in pancreatic cancer cells. IET Syst. Biol. 2012, 6:73-85.
39. Mejias-Luque R., Peiro S., Vincent A., Van Seuningen S., De Bolósa Carme I, and B.C. de, IL-6 induces MUC4 expression through gp130/STAT3 pathway in gastric cancer cell lines. Biochim. Biophys. Acta 2008, 1783:1728-1736.
40. Kunigal S., Ponnusamy M.P., Momi N., Batra S.K., Chellappan S.P. Nicotine, IFN-gamma and retinoic acid mediated induction of MUC4 in pancreatic cancer requires E2F1 and STAT-1 transcription factors and utilize different signaling cascades. Mol. Cancer. 2012, 11(24):11-24.
41. Mejias-Luque R., Linden S.K., Garrido M., Tye H., Najdovska M., Jenkins B.J., Iglesias M., Ernst M., De Bolósa Carme Inflammation modulates the expression of the intestinal mucins MUC2 and MUC4 in gastric tumors. Oncogene 2010, 29:1753-1762.
42. Thomadaki H., Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev. Clin. Lab Sci. 2006, 43:1-67.
43. Gabarra-Niecko V., Schaller M.D., Dunty J.M. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metast. Rev. 2003, 22:359-374.
44. Verbeek B.S., Vroom T.M., Rijksen G. Overexpression of c-Src enhances cell-matrix adhesion and cell migration in PDGF-stimulated NIH3T3 fibroblasts. Exp. Cell Res. 1999, 248:531-537.
45. Kaplan K.B., Swedlow J.R., Morgan D.O., Varmus H.E. C-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev. 1995, 9:1505-1517.
46. Andrianifahanana M., Moniaux N., Schmied B.M., Ringel J., Friess H., Hollingsworth M.A., Buchler M.W., Aubert J.P., Batra S.K. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin. Cancer Res. 2001, 7:4033-4040.
47. Torres M.P., Rachagani S., Purohit V., Pandey P., Joshi S., Moore E.D., Johansson S.L., Singh P.K., Ganti A.K., Batra S.K. Graviola: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. Cancer Lett. 2012, 323:29-40.
48. Shimizu T., Torres M.P., Chakraborty S., Souchek J.J., Rachagani S., Kaur S., Macha M., Ganti A.K., Hauke R.J., Batra S.K. Holy Basil leaf extract decreases tumorigenicity and metastasis of aggressive human pancreatic cancer cells in vitro and in vivo: potential role in therapy. Cancer Lett. 2013, 10.
49. Chauhan S.C., Singh A.P., Ruiz F., Johansson S.L., Jain M., Smith L.M., Moniaux N., Batra S.K. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod. Pathol. 2006, 19:1386-1394.
50. Hollingsworth M.A., Swanson B.J. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer. 2004, 4:45-60.
51. Haridas D., Chakraborty S., Ponnusamy M.P., Lakshmanan I., Rachagani S., Cruz E., Kumar S., Das S., Lele S.M., Anderson J.M., Wittel U.A., Hollingsworth M.A., Batra S.K. Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One 2011, 6:e26839.
52. Damera G., Xia B., Sachdev G.P. IL-4 induced MUC4 enhancement in respiratory epithelial cells in vitro is mediated through JAK-3 selective signaling. Respir. Res. 2006, 7(39):39.
53. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
54. Ponnusamy M.P., Singh A.P., Jain M., Chakraborty S., Moniaux N., Batra S.K. MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells. Br. J. Cancer. 2008, 99:520-526.
55. Chang Y.M., Kung H.J., Evans C.P. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 2007, 9:90-100.
56. Mitra S.K., Mikolon D., Molina J.E., Hsia D.A., Hanson D.A., Chi A., Lim S.T., Bernard-Trifilo J.A., Ilic D., Stupack D.G., Cheresh D.A., Schlaepfer D.D. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene 2006, 25:5969-5984.
57. Mitra S.K., Lim S.T., Chi A., Schlaepfer D.D. Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model. Oncogene 2006, 25:4429-4440.
58. Verma N., Singh S.K., Gupta R.C. Simultaneous determination of the stereoisomers of guggulsterone in serum by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 1998, 708:243-248.